finanzen.net
24.07.2019 01:12
Bewerten
(0)

The adoption of PDE inhibitors and drive the market at a CAGR of almost 6% during the forecast period

NEW YORK, July 23, 2019 /PRNewswire/ --

Global Phosphodiesterase (PDE) inhibitors Market: About this market

Phosphodiesterase inhibitors represent a drug class comprising drugs with a similar mechanism of action i.e. by inhibiting PDE enzymes. This phosphodiesterase inhibitors market analysis considers sales from oral, topical, and other RoA. Our analysis also considers the sales of phosphodiesterase inhibitors in Asia, Europe, North America, and ROW. In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost, and accurate dosage and stability will play a significant role in the oral segment to maintain its market position. Also, our global phosphodiesterase inhibitors market report also looks at factors such as growing adoption of poor lifestyle habits, rising prevalence of erectile dysfunction (ED), and availability of next-generation PDE inhibitors. However, potent drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and launch of generics may hamper the growth of the phosphodiesterase inhibitors industry over the forecast period.

Read the full report: https://www.reportlinker.com/p05797188/?utm_source=PRN

Global Phosphodiesterase (PDE) inhibitors Market: Overview

Rising prevalence of erectile dysfunction (ED)

The etiology of ED can be attributed to multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia. In addition, the consumption of certain medicines and substance abuse can lead to ED. As most of these factors are related to lifestyle changes, the prevalence of ED is increasing globally. Rapid urbanization, and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to ED. Thus, the increase in the incidence of ED is expected to boost the adoption of PDE inhibitors and drive the market at a CAGR of almost 6% during the forecast period.

Rising burden of chronic diseases

Chronic diseases are among the leading causes of death and contribute to a significant portion of annual healthcare expenditure. Rising healthcare costs associated with chronic diseases such as heart disease, stroke, diabetes and prediabetes is expected to lead to an increase in the adoption of PDE5 inhibitors. Thus, an increase in the economic and health burden of these diseases will ensure continuous or increased use of PDE5 inhibitors for their remission, which will promote market growth during the forecast period.

Competitive Landscape

With the presence of several major players, the global phosphodiesterase inhibitors market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphodiesterase inhibitors manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc.

Also, the phosphodiesterase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Read the full report: https://www.reportlinker.com/p05797188/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-adoption-of-pde-inhibitors-and-drive-the-market-at-a-cagr-of-almost-6-during-the-forecast-period-300889815.html

SOURCE Reportlinker

Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX am Hexensabbat wenig bewegt -- Asiens Börsen uneinheitlich -- China senkt Referenzzins erneut -- Touristikkonzern Thomas Cook verhandelt über zusätzliches Kapital -- Roche, HHLA im Fokus

TRATON-Beteiligung Navistar erwartet höhere Marge. Amazon startet Klimainitiative - 100.000 Elektro-Lieferwagen bestellt. Walgreens, FedEx und Alphabet-Tochter Wing testen Drohnen-Lieferung. HSBC hebt Enel auf 'Buy' - Kursziel angehoben.

Die 5 beliebtesten Top-Rankings

Apple nicht mehr Platz 1
Das sind die wertvollsten Unternehmen der Welt 2019
Die wertvollsten Fußballvereine der Welt 2019
Welcher Club ist am wertvollsten?
Die 12 toten Topverdiener 2019
Diese Legenden sind die bestbezahlten Toten der Welt
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
mehr Top Rankings

Umfrage

Wo sehen Sie den DAX Ende 2019?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
NEL ASAA0B733
Deutsche Bank AG514000
Daimler AG710000
Microsoft Corp.870747
CommerzbankCBK100
Apple Inc.865985
Amazon906866
Ballard Power Inc.A0RENB
BASFBASF11
Infineon AG623100
EVOTEC SE566480
E.ON SEENAG99
BayerBAY001
Volkswagen (VW) AG Vz.766403